{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-073817","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.556586+00:00","generated_at":"2026-06-13T19:03:32.363985+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"uniQure reports $100M HEMGENIX milestone; AMT-130 shows preserved function at 24 months in HD trial","bullets":["$100M milestone achieved from CSL Behring for first US commercial sale of HEMGENIX (hemophilia B gene therapy); payment due within 30 days.","AMT-130 well-tolerated; no treatment-emergent adverse events led to discontinuation. DSMB recommends continuing development.","Low-dose cohort showed preserved function at 24 months; TMS improved 1.8 points vs natural history, TFC 0.8, cUHDRS 0.9.","Mean CSF NfL 12.9% below baseline at 24 months in low-dose cohort vs predicted 22.9% increase in natural history.","Plan to complete EU enrollment in Q3 2023, start third US cohort in H2 2023, and hold regulatory interactions by Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-073817","json":"https://secwatch.observer/filing/0001104659-23-073817.json","markdown":"https://secwatch.observer/filing/0001104659-23-073817.md","text":"https://secwatch.observer/filing/0001104659-23-073817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923073817/0001104659-23-073817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923073817/tm2319377d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:03:32.363985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}